Takeda Pharmaceutical Company has exercised its option to acquire Maverick Therapeutics for a pre-negotiated upfront payment and potential development and regulatory milestones totalling up to $525m.

Through this acquisition, Takeda will be able to expand its novel immuno-oncology portfolio.

The latest development follows a multi-year collaboration signed by the companies in 2017 for developing conditionally active T-cell engager therapies, though which Takeda received an equity stake and an exclusive right to buy Maverick after five years.

Under the agreement, Takeda will gain access to Maverick’s T-cell engager COBRA platform and a wide development portfolio, including the latter’s lead development candidate, TAK-186 (MVC-101) and TAK-280 (MVC-280).

At present, TAK-186 is in a Phase I/II study for treating EGFR-expressing solid tumours while TAK-280 is set to enter the clinic for treating B7H3-expressing solid tumour patients.

On closing of the deal, employees of Maverick, including its scientists’ team will join Takeda’s Research & Development organisation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Takeda oncology therapeutic area unit head Chris Arendt said: “Collaboration is paramount to our R&D strategy and our pursuit of novel approaches to treat cancer.

“Maverick’s cutting-edge COBRA platform is an exciting addition to our oncology portfolio that provides a novel conditional bioengineering approach to advance redirected immunotherapies against solid tumours.”

Designed to safely target a wide range of solid tumours with highly specific and potent activity, Maverick’s COBRA platform can limit toxicities in normal tissues.

As compared to standard T-cell engaging immunotherapies that are systemically active on administration, COBRA-engineered, protein-based therapies can potentially exploit the tumour microenvironment, prompting T-cell-mediated killing only at the tumour site without causing damage to healthy tissues.

Last week, Takeda signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn).

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now